H. Lundbeck A/S
5 products tracked · names used in filings: H. Lundbeck A/S
Upcoming milestones
No upcoming milestones listed.
Recent milestones
No recent milestones.
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Acrescent memantine hydrochloride;donepezil hydrochloride | Refused | |
| 🇪🇺 | Vyepti eptinezumab | Authorised | 2022-01-24 |
| 🇪🇺 | Brintellix vortioxetine | Authorised | 2013-12-18 |
| 🇪🇺 | Selincro nalmefene | Authorised | 2013-02-24 |
| 🇪🇺 | Ebixa memantine | Authorised | 2002-05-15 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.